Compare GSK plc (GSK) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Morgan Stanley — how do they compare? GSK plc trades at $52.44 (market cap $101.34B), while Morgan Stanley trades at $220.52 (market cap $359.28B). The key difference: Morgan Stanley is far larger — about 3.5× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MS | |
|---|---|---|
Market Cap | $101.34B | $359.28B |
Sector | Health | Financials |
52-Week High | $61.18 | $228.42 |
52-Week Low | $36.20 | $139.09 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Morgan Stanley (MS) trades at $228.17, up 3.2% with strong technical and fundamental momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth from $57.6B in 2024 to $66.0B in 2025. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus at Buy (53.85%) and $229 price target. Key opportunities include sustained earnings growth and strategic initiatives, while risks involve volatile cash flows and high debt levels. The stock presents a balanced risk-reward profile for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
